Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Immunol Res. Author manuscript; available in PMC 2010 November 23.
Published in final edited form as:
PMCID: PMC2990789

Leukocyte integrins and their ligand interactions


Although critical for cell adhesion and migration during normal immune-mediated reactions, leukocyte integrins are also involved in the pathogenesis of diverse clinical conditions including autoimmune diseases and chronic inflammation. Leukocyte integrins therefore have been targets for anti-adhesive therapies to treat the inflammatory disorders. Recently, the therapeutic potential of integrin antagonists has been demonstrated in psoriasis and multiple sclerosis. However, current therapeutics broadly affect integrin functions and, thus, yield unfavorable side effects. This review discusses the major leukocyte integrins and the anti-adhesion strategies for treating immune diseases.

Keywords: Integrin, LFA-1, Mac-1, VLA-4


Integrins are adhesive transmembrane receptors that mediate bidirectional signal transmission between the cell and its environment. “Inside-out” integrin signaling, often stimulated by chemokines or chemoattractive cytokines, regulates the affinity of the integrin for ligand binding. “Outside-in” signaling, which can involve ligand binding and receptor clustering, triggers intracellular signaling pathways that control diverse cell functions. Integrins have critical roles at each step during the process of leukocyte emigration from the blood to inflammatory sites and lymphoid tissues. Heterodimeric integrins expressed predominantly by leukocytes consist of a β2 subunit coupled with one of several α subunit counterparts (αLβ2, αMβ2, αXβ2, and αDβ2), or an α4 subunit with its β subunit counterparts (α4β1 and α4β7). These leukocyte integrins are dynamically up- or down-regulated depending on the stage of leukocyte activation and extravasation, and each integrin has specific functions contributing to leukocyte movements. Insufficient integrin activity contributes to recurrent infectious episodes and impaired wound healing, and excessive integrin activity leads to a sustained and exaggerated inflammatory response with associated tissue damage. Antagonistic monoclonal antibodies and small molecules targeted against leukocyte integrins have been developed for monotheraphies to treat autoimmune and inflammatory diseases. These function-blocking reagents have generally been shown to be efficacious, although their mechanisms of action still need to be defined in detail. Hereby, we summarize the expression and ligand interactions of LFA-1, Mac-1 and VLA-4 in the immune response and discuss the current therapeutic strategies for each.


1. Expression

Lymphocyte function-associated antigen-1 (integrin LFA-1, αLβ2, CD11a/CD18), is expressed exclusively by leukocytes, and plays a role in leukocyte recruitment to inflammatory sites and lymphoid tissues [1]. LFA-1 is involved in various cell-cell interactions, such as T cells-antigen presenting cells, B cells-T cells and natural killer (NK) cells-target cells [2], and in the formation of the immunological synapse [3]. The importance of LFA-1 is demonstrated in β2 integrin-deficient patients with leukocyte adhesion deficiency (LAD). LAD patients exhibit a deficiency to clear pathogens, recurrent infections and death at an early age [1]. Animal studies using CD18-deficient mice demonstrated defects in a wide range of immune responses, including attenuated recruitment of myeloid cells [4]. In addition, in CD11a- and CD18-deficient mice, both subunits of LFA-1 were shown to be critical for host resistance against Mycobacterium tuberculosis infection [5].

2. Ligands

LFA-1 binds to intercellular adhesion molecules (ICAMs), including ICAM-1, ICAM-2, ICAM-3, ICAM-4, ICAM-5 [610], and the junctional adhesion molecule (JAM)-1 [11]. Among the ICAMs, ICAM-1 is the principal ligand for LFA-1. LFA-1 binds the D1 domain of the ICAM-1 molecule that consists of five tandem immunoglobulin superfamily (IgSF) domains [12]. It was shown that Glu34 in the D1 domain of ICAM-1 binds to the Mg2+ within the metal ion-dependent adhesion site (MIDAS) of the αL I domain and stimulates conformational change of the integrin [13]. The interaction of LFA-1 with ICAM-2 and ICAM-3 is involved in diapedesis and antigen recognition, respectively, and ICAM-1 is involved in both processes [6,14]. ICAM-4, a red cell membrane glycoprotein originally named Landsteiner-Wiener (LW) blood group antigen [15], is still being investigated for its physiological role in binding to LFA-1, but may be involved in erythropoesis [10]. ICAM-5 (telencephalin), which is expressed by neurons, is suggested to act as an adhesion molecule for leukocyte trafficking in the central nervous system [9]. JAM-1 is a recently discovered ligand for LFA-1 and plays an important role in the sequential steps of adhesion and transmigration during the recruitment of memory T cells and neutrophils [11].

3. Signaling and regulation

Many signaling molecules have emerged as players in inside-out and outside-in signaling pathways for regulating LFA-1 function. Rap-1, a member of the Ras family of small GTPases, is an upstream regulator that modulates the affinity and avidity of LFA-1 [16]. The Ras proteins, including Rap-1, reversibly cycle between GTP-bound active and GDP-bound forms, regulated by guanine exchange factors (GEFs) and GTPase-activating proteins (GAPs). Calcium and diacylglycerol-regulated guanine nucleotide exchange factor I (CalDAG-GEFI) is a key GEF that activates Rap-1 by releasing GDP and loading GTP in response to calcium and DAG [17]. Therefore, CalDAG-GEFI plays a critical role in Rap-1-mediated integrin-dependent immune responses, such as platelet aggregation and leukocyte motility. It has been reported that CalDAG-GEFI knockout mice are deficient in integrin-dependent platelet aggregation [18]. Although Rap-1 is an important inside-out activator of LFA-1 and VLA-4, the regulation of Rap-1 by CalDAG-GEFI is exclusively involved in LFA-1 activation induced by chemokines and phorbol 12-myristate 13-acetate (PMA) [19]. A recent study reported that one of the LAD syndromes, LAD-III, involves the deficient expression of CalDAG-GEFI in lymphocytes, neutrophils, and platelets [20].

Regulator of adhesion and polarization enriched in lymphocytes (RAPL), an effector molecule that associates with Rap-1, is crucially involved in Rap-1-mediated integrin activation during T cell receptor (TCR) and chemokine triggered LFA-1 adhesion to ICAM-1 [21]. In Rap-1/RAPL-mediated LFA-1 activation, the Ser/Thr kinase Mst1 is a downstream effector molecule of RAPL that binds to RAPL in association with the cytoplasmic domain of the αL subunit of LFA-1 [22]. RAPL switches the integrin from the low affinity to the high affinity state and stimulates the extension of the extracellular headpiece of the integrin, whereas Mst1 plays an apparent role in the transport of active LFA-1 to the leading edge of motile cells [22,23]. Studies of RAPL knockout mice have shown that RAPL-deficient lymphocytes exhibit impaired ability in homing to lymphoid tissues, are much less adherent to ICAM-1 and fibronectin, and are deficient in migration [24]. Thus, RAPL and Mst1 are critical regulators of leukocyte trafficking via LFA-1. In addition to RAPL, Rap1–GTP interacting adapter molecule (RIAM) is also a crucial effector molecule for Rap-1-mediated integrin activation [24,25], though RIAM and RAPL act through independent signaling pathways [26]. RIAM associated with Rap-1 stimulates the binding of talin to the β subunit and subsequent opening of the extracellular headpiece of the integrin for high affinity ligand binding.

RhoH, a member of the Rho family of small GTPases, is deficient in GTPase activity and exists constitutively in a GTP-bound state [27]. RhoH has been shown to be a leukocyte-specific inhibitory molecule that negatively regulates LFA-1 activation [28]. Thus, in the absence of positive regulatory signals, such as Rap-1, RhoH maintains LFA-1 in the basal state and leukocytes remain in their resting non-adhesive state.

Jun activating binding protein-1 (JAB-1) is a transcriptional co-activator that interacts with LFA-1 [29]. JAB-1 is expressed in the nucleus and the cytoplasm of cells, and a fraction of JAB-1 is colocalized with LFA-1 at the membrane. JAB-1 is implicated as an outside-in signaling modulator, as LFA-1 cross-linking triggers an increase of JAB-1 in the nucleus and activation of activator protein-1 (AP-1) [29].

Cytohesin-1 is a signaling molecule that interacts with the cytoplasmic domain of the β2 subunit of LFA-1 and thus regulates LFA-1 activation [30]. Cytohesin-1 has a pleckstrin homology (PH) domain and a domain homologous to the yeast SEC7, a GEF for ADF ribosylation factor (ARF)-GTPases [30,31]. The molecule is suggested to be involved in inside-out and outside-in signaling [32,33].

Myosin II in nonmuscle cells is involved in cytokinesis and cell migration [34]. There are three isoforms of human nonmuscle myosin, termed MyH9, MyH10, and MyH14 [35]. Among them, MyH9 is expressed in T cells and recruited to LFA-1 positioned at the uropod during migration [36]. When the association of MyH9 and LFA-1 was inhibited, T cells migrating on ICAM-1 exhibit extremely elongated uropods and are deficient in tail detachment. Consequently, T cell migration mediated by LFA-1 on ICAM-1 was inhibited. Thus, MyH9 is a crucial regulator of the mechanical link between LFA-1 and the cytoskeleton, and is important for LFA-1 de-adhesion during T cell migration.

4. Clinical implications

LFA-1 has been targeted with specific antagonists to treat lymphocyte-based diseases including psoriasis, rheumatoid arthritis and organ transplant rejection [2]. Efalizumab, a monoclonal antibody to the αL subunit of LFA-1, selectively and reversibly inhibits trafficking of T cells and successfully treats plaque psoriasis with moderate-to-severe symptoms by blocking the interaction of T cells with Langerhans cells, endothelial cells and keratinocytes [37,38]. Efalizumab was also shown to inhibit the development of allergen-induced cellular inflammatory responses and attenuate the late asthmatic response [39]. The antagonist-driven therapies for LFA-1 function may potentially be used for the treatment of bone marrow graft failure, kidney allograft rejection, asthma and graft-versus-host disease [4043]. As described above, Rap-1 and Mst1 are involved in αL subunit binding with RAPL and subsequent LFA-1 activation. Thus, instead of global blockade of Rap-1/RAPL, which is involved in regulating multiple integrins, the interaction of Rap-1/RAPL with αL or Mst1 has been proposed as an alternative therapeutic target for the selective inhibition of LFA-1 in the treatment of inflammatory diseases with minimal side effects [44]. However, it is still unclear how these molecules interact with each other in detail and additional molecular studies are required before therapies can be developed.


1. Expression

Macrophage antigen-1 (integrin Mac-1, αMβ2, CD11b/CD18) is expressed by cells of the myeloid lineage [45,46], including neutrophils, monocytes, macrophages and dendritic cells. Mac-1 is also expressed, to a limited extent, by certain subsets of T lymphocytes [47]. In response to inflammatory stimuli, the cell surface expression of Mac-1 on neutrophils [48] and monocytes [49] is upregulated by an order of magnitude by the rapid delivery of stores within secondary granules [50]. However, studies indicate that this increase in Mac-1 expression is neither sufficient nor necessary for the adhesive function of Mac-1 during leukocyte recruitment and extravasation. Inhibition of degranulation or depletion of granule stores did not affect the adherence of neutrophils to cultured endothelium in the presence of inflammatory stimuli [51]. In addition, blocking only a small portion of Mac-1 on stimulated neutrophils with antibodies specific to the high affinity I domain resulted in nearly complete inhibition of adhesion to ICAM-1 and fibrinogen [52], indicating that the increase in integrin affinity, rather than density, regulates neutrophil recruitment. The increased cell surface expression of Mac-1 after degranulation does not persist when neutrophils are exposed to stimulatory agents for an extended time [53]. In response to the bacterial product N-formyl-Met-Leu-Phe peptide (fMLP) in the presence of other pro-inflammatory factors, or to PMA alone, the amino-terminal portion of the αM subunit is cleaved by a Ser proteinase resulting in a decrease in Mac-1-dependent neutrophil adhesion [53]. The precise role of Mac-1 in the sequential steps of the inflammatory cascade remains a topic of active investigation. Recent studies have surprisingly found that Mac-1 deficiency does not significantly impair the adhesion of neutrophils to the endothelium during inflammation, but that Mac-1 alone mediates intraluminal migration after neutrophil arrest [54].

2. Ligands

Mac-1 is the most promiscuous integrin with more than 30 reported ligands. The primary Mac-1 ligand binding activity resides within the I domain at the amino terminal portion of the αM subunit [55]. The broad range of Mac-1 ligands includes members of the ICAM family [56,57], extracellular matrix components such as fibrinogen [58], complement C3 fragment C3bi [59], and protein and nonprotein microbial ligands [60]. Of particular significance in leukocyte recruitment and emigration are the ICAMs. While LFA-1 binds to the D1 domain of ICAM-1, Mac-1 recognizes the ICAM-1 D3 domain [61]. In vitro assays suggest that when both integrins are present, the LFA-1/ICAM-1 interaction takes precedence, indicating that LFA-1 and Mac-1 may compete for binding [62]. However, the binding characteristics of the integrin-ICAM-1 interaction appears to be much more complex in vivo where LFA-1 has been shown to play a dominant role over Mac-1 in mediating the firm adhesion of leukocytes to the endothelium [63], but Mac-1 interacts with ICAM-1 to mediate intraluminal crawling after leukocyte arrest [54].

Several studies have investigated the molecular basis for Mac-1 ligand recognition. In one of these studies, an important sequence in the αM I domain was identified. A chimeric integrin was constructed in which the βD-α5 loop-α5 helix segment of the αM I domain was inserted into and replaced the complementary sequence within the αL I domain of LFA-1 [64]. This integrin chimera was able to bind to several Mac-1 ligands, including fibrinogen, fibronectin, ovalbumin, and tissue culture plastic, to a similar extent as wild type Mac-1 [64]. Three amino acids (Phe246, Asp254, Pro257) within this region of the αM I domain were identified as critical for Mac-1-dependent ligand binding [64]. However, it is likely that this segment of the αM I domain does not solely mediate Mac-1 binding, as cells expressing the chimeric integrin in the study described above did not spread on Mac-1 ligand substrates to the same extent as cells expressing wild type Mac-1 [64]. In a separate study, ligand recognition sequences in three distinct regions of the αM I domain, including the segment described above, were found to comprise the C3bi binding pocket [65]. Given the broad and diverse range of ligands that have been described for Mac-1, it is apparent that multiple mechanisms exist by which Mac-1 recognizes its binding partners.

3. Signaling and regulation

While the proximal events that regulate LFA-1 activation are relatively well defined, the molecular details of inside-out Mac-1 activation are poorly understood and remain a subject of intense investigation. There is an abundance of experimental evidence demonstrating that LFA-1 and Mac-1 are distinctly regulated. Several studies have shown that different chemokines and chemoattractants stimulate inside-out activation of LFA-1 or Mac-1 [66,67]. In a neutrophil chemotaxis assay, fMLP stimulated Mac-1-mediated migration in a p38 mitogen-activated protein kinase (MAPK)-dependent manner, whereas IL-8 stimulated migration mediated by LFA-1 that relied on phosphoinositide 3-kinase (PI3K) signaling [67]. That LFA-1 and Mac-1 are differentially regulated suggests an important role for the integrin α subunit in regulating their activation, and recent data support this hypothesis. Constitutive phosphorylation of a Ser residue near the integrin cytosolic C-terminus is shared by the αL subunit of LFA-1 [68] and αM subunit of Mac-1 [69], and has been shown to be important for activation and affinity upregulation. Mutating this Ser in the αM subunit blocked the conformational rearrangements involved in Mac-1 activation, including extension of the extracellular domain and opening of the I domain, as indicated by activation-specific antibody recognition [69]. However, a similar mutation in LFA-1 did not affect the exposure of these activation epitopes, indicating that the α subunits of Mac-1 and LFA-1 differentially regulate their activation [69]. Further research is needed to determine the mechanism by which the αM cytoplasmic tail regulates Mac-1 activation and the upstream signaling molecules that are involved.

4. Clinical implications

Few anti-adhesion therapeutics targeting Mac-1 have been pursued clinically and developed commercially. Recombinant neutrophil inhibitory factor (rNIF), whose target is the Mac-1 I domain [70], was shown in animal models to inhibit neutrophil recruitment to sites of cerebral ischemia and reduce inflammation, a contributor to ischemic injury after stroke [71]. Phase II clinical trials of rNIF, however, were abandoned after the drug failed to improve the recovery of stroke patients [72].

Although there have been few clinical trials of anti-Mac-1 agents, alteration of Mac-1 expression or activation state has been implicated in the efficacy of drugs not specifically targeting Mac-1. Abciximab was designed as a Fab fragment against the integrin αIIbβ3 to inhibit platelet aggregation, and used to prevent ischemic complications and restenosis in patients undergoing angioplasty [73]. Significant improvement in procedural complications [73,74], the short-term need for revascularization [74], and long-term mortality [75] was observed in patients treated with abciximab. However, the molecular mechanisms for the clinical benefits of abciximab are not clear. Activated leukocytes and enhanced Mac-1 expression, but not LFA-1, have been identified as markers of restenosis risk [7678]. Subsequent studies suggested that regulation of Mac-1 by abciximab could contribute to the inhibition of intimal thickening that occurs after angioplasty, as abciximab was shown to bind to monocytes and inhibit Mac-1-mediated adhesion to fibrinogen, C3bi, and the coagulation factor X [79]. Moreover, an anti-Mac-1 antibody reduced leukocyte recruitment and neointimal thickening after stent-induced injury in rabbits [80]. These results suggest that Mac-1 may be an effective target for therapies administered during vascular intervention.

Mac-1-binding agents are also being studied for use in cancer therapies. Anti-tumor antibodies can effectively stimulate the deposition of the opsonin C3bi on tumor cell surfaces. However, in the absence of Mac-1-associated polysaccharides, neutrophil binding to C3bi via Mac-1 does not result in degranulation or phagocytosis [81]. β-glucans are long glucose polymers that have been shown to bind to a lectin domain in the carboxy-terminal portion of the αM subunit [82] and prime Mac-1 for cytotoxic activity [83]. In conjunction with antibody therapies, β-glucan has been shown to induce tumor regression and increase survival rate in animal models [84,85]. In these studies, neutrophils were found to be the primary effector cells in the therapeutic response [84]. Cancer immunotherapies in which β-glucan is employed as an immunoadjuvant have been used clinically since the 1980s.

Antibodies [86] and antibody-derived cyclic peptides [87] that exclusively recognize the active form of the Mac-1 I domain have been described. These reagents specifically block the binding of certain ligands to activated Mac-1, including ICAM-1 and fibrinogen, but not C3bi [87]. The antibody-derived blocking peptides inhibited the adhesion of stimulated monocytes to immobilized fibrinogen, while unstimulated cells were still able to bind fibrinogen under both static and flow conditions [87]. These studies suggest that therapeutics specifically targeting the active form of Mac-1 may be effective in treating inflammatory diseases, while preserving normal host defense functions such as phagocytosis of bacteria by recognition of C3bi [87].


1. Expression

Very late antigen-4 (integrin VLA-4, α4β1, CD49d/CD29) is expressed by most resting lymphocytes, eosinophils, and monocytes [88,89]. In contrast to other integrins, the expression level of VLA-4 is not considerably increased in response to lymphocyte activation [41]. However, it was shown that VLA-4 expression is upregulated during the maturation of monocyte-derived dendritic cells [90]. VLA-4 also plays a role in the development and differentiation of several tissues and cell types [41]. VLA-4 is expressed by muscle cells and, in association with VCAM-1, is involved in myotube formation and alignment of the secondary myoblasts [91]. VLA-4 expression is also found in thymic epithelial cells and the integrin is suggested to play a role in thymus epithelial cell-thymocyte interactions [92]. VLA-4 is expressed by bone marrow CD34+ haematopoietic stem cells and thus related to mobilization of these cells and inhibition of homing of peripheral blood progenitors [93]. Consistent with these data, homozygous null mutation of VLA-4 (α4 subunit deficient) in mice resulted in embryonic lethality with defects in placentation and the development of the epicardic vessels [94].

2. Ligands

The α4 subunit of VLA-4 lacks the I domain that is a critical structural component of other integrins for which the α subunit I domain is the ligand binding site. Instead, the I-like domain in the β1 subunit mediates ligand binding to VLA-4 [89]. VLA-4 mediates cell-extracellular matrix adhesion by binding to an LDV motif in an alternatively spliced region of fibronectin, the connecting segment 1 (CS-1). VLA-4 also mediates cell-cell adhesion by binding to an IDS motif in VCAM-1, a molecule containing six tandem IgSF domains. VLA-4 also interacts with JAM-2 expressed by endothelial cells following prior engagement of JAM-2 with JAM-3 expressed by T cells [95]. JAMs are also members of the IgSF expressed at cell-cell contacts in leukocytes, platelets, epithelial and endothelial cells, and play a role in leukocyte-endothelial cell interactions and cell polarity regulation [96].

3. Signaling and regulation

VLA-4 is an important component in immune function, playing a role in lymphocyte differentiation and homing, as well as in tissue-specific migration during inflammation [97]. α4 integrins, including VLA-4 and α4β7, have tightly regulated multi-step functions during rolling and arrest of leukocytes on the endothelium [98,99]. VLA-4 is also involved in cell-cell adhesion of leukocytes, such as at the immunological synapse [100]. Although the LFA-1-ICAM-1 interaction is crucial in the structure of the immunological synapse, the VLA-4-VCAM-1 interaction also contributes to immunological synapse formation [101]. Cytoskeletal adaptor molecules, such as Rap-1, paxillin, and talin, which regulate integrin adhesiveness, are involved in VLA-4 function during immune responses.

Inside-out signaling triggered by the small GTPase Rap-1 allows integrins on circulating leukocytes to become activated, resulting in ligand binding and cell adhesion. Rap-1 is an important regulator of b1 integrins, including VLA-4, by mediating inside-out signaling [102] and is activated by various external stimuli, including TCR- and CD31-induced adhesion [103]. Rap-1 induces the binding of the cytoskeletal protein talin to the integrin cytoplasmic tail, which promotes integrin activation.

Paxillin is a signaling molecule that interacts with the cytoplasmic domain of the α4 integrin subunit in a phosphorylation-dependent manner and subsequently triggers lymphocyte migration by downstream regulation of effector molecules [104,105]. When the α4 integrin is phosphorylated at Ser988 by protein kinase A, its binding to paxillin is inhibited at the tailing edge of the cell and paxillin-free α4 integrin is localized at the leading edge of the cell [104]. The localization of phosphorlayted α4 complexed with paxillin at the leading edge of migrating cells augments effective leukocyte migration [105]. Thus, the spatially-regulated interaction of α4 integrin with paxillin is a critical signaling step for cell motility.

4. Clinical implications

VLA-4 is implicated in the pathogenesis of autoimmune diseases and chronic inflammation such as multiple sclerosis [106], Crohn’s disease [107], asthma [108], stroke [109], rheumatoid arthritis [110], and inflammatory bowel disease [111]. Therefore, VLA-4 has been therapeutically targeted by antagonists such as blocking antibodies and ligand mimetic small molecules [112,113]. Multiple sclerosis is a neurological disease caused by autoimmune T cells. Immune reactions during early steps in the development of multiple sclerosis lesions include transmigration of CD4+ T cells (TH1 and TH17) from the blood to the central nervous system (CNS) across the blood brain barrier, where VLA-4 plays critical roles in the migration process [114,115]. Natalizumab, a monoclonal antibody to the α4 subunit, blocks binding of VLA-4 and α4β7 to VCAM-1 and MadCAM-1, respectively. Natalizumab showed efficacy by inhibiting inflammatory lesion in multiple sclerosis [116]. The number of CD4+ and CD8+ T cells, CD19+ B cells, and CD138+ plasma cells in the cerebrospinal fluid (CSF) was significantly reduced in Natalizumab-treated patients.

Although the current therapeutics to block α4 integrin function have shown positive effects in the treatment of autoimmune diseases, they may also have unfavorable side effects on VLA-4-dependent processes, such as development, hematopoiesis and immune surveillance. Natalizumab treatment for multiple sclerosis patients resulted in the development of progressive multifocal encephalopathy (PML) and led to patient death in a few cases [117119]. PML is a demyelinating disease of the CNS that occurs in immune-suppressed patients. It results from lytic infection of oligodendrocytes in the CNS by the John Cunningham (JC) polyomavirus [120]. It has been reported that 1 in 1000 cases of Natalizumab treatments could lead to PML [121]. Thus, it is important to develop more specific antagonistic agents for targeting α4 integrin function that affect leukocyte trafficking in an inflammatory-site specific manner rather than global blockade of integrin function.

Therefore, an alternative approach to regulate α4 integrin signaling has been suggested for disease treatment [122]. As described above, paxillin binds to the α4 integrin in a phosphorylation-dependent manner and regulates lymphocyte migration [104,105]. Therefore, the α4-paxillin signaling pathway could be a therapeutic target for site-specific blockade of integrin function [122]. It may be advantageous to treat diseases involving α4 integrins by selectively blocking cell migration to the inflammatory site, while minimizing the obstruction of other functions of α4 integrins.


In general, anti-adhesive therapies targeting the major leukocyte integrins LFA-1, Mac-1 and VLA-4 have proven to be relatively successful in the clinic. However, the current approaches block integrin ligand binding in a non-specific manner and, thus, impair the normal immune response and compromise the health of the patient. Furthermore, ligand-mimetic small molecule integrin antagonists have failed in the clinic, presumably as a result of outside-in signaling induced by the stabilization of an active integrin conformation [123,124]. Alternative therapies have been proposed that include specifically targeting the active form of the integrin [87] or regulating the adhesive function of integrins through their associated intracellular adaptor proteins [44]. The development of reagents with higher selectivity for specific integrin populations involved in the disease state may provide more efficacious treatments for both chronic and acute immune pathologies.

Table I
Leukocyte integrins


This project was supported by NIH HL087088 (M.K.), and NIH HL18208 (M.K.).


1. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multi-step paradigm. Cell. 1994;76:301–314. [PubMed]
2. Shimaoka M, Springer TA. Therapeutic antagonists and the conformational regulation of integrin structure and function. Nat Rev Drug Disc. 2003;2:703–716. [PubMed]
3. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML. The immunological synapse: a molecular machine controlling T cell activation. Science. 1999;285:221–227. [PubMed]
4. Ulyanova T, Priestley GV, Banerjee ER, Papayannopoulou T. Unique and redundant roles of alpha4 and beta2 integrins in kinetics of recruitment of lymphoid vs myeloid cell subsets to the inflamed peritoneum revealed by studies of genetically deficient mice. Exp Hematol. 2007;35:1256–1265. [PMC free article] [PubMed]
5. Ghosh S, Chackerian AA, Parker CM, Ballantyne CM, Behar SM. The LFA-1 adhesion molecule is required for protective immunity during pulmonary Mycobacterium tuberculosis infection. J Immunol. 2006;176:4914–4922. [PubMed]
6. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) Cell. 1987;51:813–819. [PubMed]
7. de Fougerolles AR, Stacker SA, Schwarting R, Springer TA. Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. J Exp Med. 1991;174:253–267. [PMC free article] [PubMed]
8. de Fougerolles AR, Qin X, Springer TA. Characterization of the function of ICAM-3 and comparison to ICAM-1 and ICAM-2 in immune responses. J Exp Med. 1994;179:619–629. [PMC free article] [PubMed]
9. Tian L, Kilgannon P, Yoshihara Y, Mori K, Gallatin WM, Carpen O, Gahmberg CG. Binding of T lymphocytes to hippocampal neurons through ICAM-5 (telencephalin) and characterization of its interaction with the leukocyte integrin CD11a/CD18. Eur J Immunol. 2000;30:810–818. [PubMed]
10. Ihanus E, Uotila L, Toivanen A, Stefanidakis M, Bailly P, Cartron JP, Gahmberg CG. Characterization of ICAM-4 binding to the I domains of the CD11a/CD18 and CD11b/CD18 leukocyte integrins. Eur J Biochem. 2003;270:1710–1723. [PubMed]
11. Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 2002;3:151–158. [PubMed]
12. Wang J, Springer TA. Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Immunol Rev. 1998;163:197–215. [PubMed]
13. Shimaoka M, Xiao T, Liu J-H, Yang Y, Dong Y, Jun C-D, McCormack A, Zhang R, Joachimiak A, Takagi J, Wang J-h, Springer TA. Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell. 2003;112:99–111. [PubMed]
14. van Seventer G, Shimizu Y, Horgan K, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol. 1990;144:4579–4586. [PubMed]
15. Mallinson G, Martin PG, Anstee DJ, Tanner MJ, Merry AH, Tills D, Sonneborn HH. Identification and partial characterization of the human erythrocyte membrane component(s) that express the antigens of the LW blood-group system. Biochem J. 1986;234:649–652. [PubMed]
16. Katagiri K, Hattori M, Minato N, Irie S, Takatsu K, Kinashi T. Rap1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase. Mol Cell Biol. 2000;20:1956–1969. [PMC free article] [PubMed]
17. Kawasaki H, Springett GM, Toki S, Canales JJ, Harlan P, Blumenstiel JP, Chen EJ, Bany IA, Mochizuki N, Ashbacher A, Matsuda M, Housman DE, Graybiel AM. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc Natl Acad Sci U S A. 1998;95:13278–13283. [PubMed]
18. Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, Housman DE, Graybiel AM. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med. 2004;10:982–986. [PubMed]
19. Ghandour H, Cullere X, Alvarez A, Luscinskas FW, Mayadas TN. Essential role for Rap1 GTPase and its guanine exchange factor CalDAG-GEFI in LFA-1 but not VLA-4 integrin mediated human T-cell adhesion. Blood. 2007;110:3682–3690. [PubMed]
20. Pasvolsky R, Feigelson SW, Kilic SS, Simon AJ, Tal-Lapidot G, Grabovsky V, Crittenden JR, Amariglio N, Safran M, Graybiel AM, Rechavi G, Ben-Dor S, Etzioni A, Alon R. A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets. J Exp Med. 2007;204:1571–1582. [PMC free article] [PubMed]
21. Kinashi T, Katagiri K. Regulation of lymphocyte adhesion and migration by the small GTPase Rap1 and its effector molecule, RAPL. Immunol Lett. 2004;93:1–5. [PubMed]
22. Katagiri K, Imamura M, Kinashi T. Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat Immunol. 2006;7:919–928. [PubMed]
23. Katagiri K, Maeda A, Shimonaka M, Kinashi T. RAPL, a novel Rap1-binding molecule, mediates Rap1-induced adhesion through spatial regulation of LFA-1. Nat Immunol. 2003;4:741–748. [PubMed]
24. Katagiri K, Ohnishi N, Kabashima K, Iyoda T, Takeda N, Shinkai Y, Inaba K, Kinashi T. Crucial functions of the Rap1 effector molecule RAPL in lymphocyte and dendritic cell trafficking. Nat Immunol. 2004;5:1045–1051. [PubMed]
25. Lafuente EM, van Puijenbroek AA, Krause M, Carman CV, Freeman GJ, Berezovskaya A, Constantine E, Springer TA, Gertler FB, Boussiotis VA. RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. Dev Cell. 2004;7:585–595. [PubMed]
26. Rose DM, Alon R, Ginsberg MH. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev. 2007;218:126–134. [PubMed]
27. Li X, Bu X, Lu B, Avraham H, Flavell RA, Lim B. The hematopoiesis-specific GTP-binding protein RhoH is GTPase deficient and modulates activities of other Rho GTPases by an inhibitory function. Mol Cell Biol. 2002;22:1158–1171. [PMC free article] [PubMed]
28. Cherry LK, Li X, Schwab P, Lim B, Klickstein LB. RhoH is required to maintain the integrin LFA-1 in a nonadhesive state on lymphocytes. Nat Immunol. 2004;5:961–967. [PubMed]
29. Bianchi E, Denti S, Granata A, Bossi G, Geginat J, Villa A, Rogge L, Pardi R. Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature. 2000;404:617–621. [PubMed]
30. Kolanus W, Nagel W, Schiller B, Zeitlmann L, Godar S, Stockinger H, Seed B. αLβ2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1, a cytoplasmic regulatory molecule. Cell. 1996;86:233–242. [PubMed]
31. Weber KS, Weber C, Ostermann G, Dierks H, Nagel W, Kolanus W. Cytohesin-1 is a dynamic regulator of distinct LFA-1 functions in leukocyte arrest and transmigration triggered by chemokines. Curr Biol. 2001;11:1969–1974. [PubMed]
32. Mor A, Dustin ML, Philips MR. Small GTPases and LFA-1 reciprocally modulate adhesion and signaling. Immunol Rev. 2007;218:114–125. [PubMed]
33. Perez OD, Mitchell D, Jager GC, South S, Murriel C, McBride J, Herzenberg LA, Kinoshita S, Nolan GP. Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nat Immunol. 2003;4:1083–1092. [PubMed]
34. Bresnick AR. Molecular mechanisms of nonmuscle myosin-II regulation. Curr Opin Cell Biol. 1999;11:26–33. [PubMed]
35. Berg JS, Powell BC, Cheney RE. A millennial myosin census. Mol Biol Cell. 2001;12:780–794. [PMC free article] [PubMed]
36. Morin NA, Oakes PW, Hyun YM, Lee D, Chin EY, King MR, Springer TA, Shimaoka M, Tang JX, Reichner JS, Kim M. Nonmuscle myosin heavy chain IIAmediates integrin LFA-1 de-adhesion during T lymphocyte migration. J Exp Med. 2008;205:195–205. [PMC free article] [PubMed]
37. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004–2013. [PubMed]
38. Simmons DL. Anti-adhesion therapies. Curr Opin Pharmacol. 2005;5:398–404. [PubMed]
39. Gauvreau GM, Becker AB, Boulet LP, Chakir J, Fick RB, Greene WL, Killian KJ, O'Byrne PM, Reid JK, Cockcroft DW. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol. 2003;112:331–338. [PubMed]
40. Fischer A, Friedrich W, Fasth A, Blanche S, Le Deist F, Girault D, Veber F, Vossen J, Lopez M, Griscelli C, et al. Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European Group for Immunodeficiency/European Group for Bone Marrow Transplantation report. Blood. 1991;77:249–256. [PubMed]
41. Gonzalez-Amaro R, Mittelbrunn M, Sanchez-Madrid F. Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords? Immunology. 2005;116:289–296. [PubMed]
42. Le Mauff B, Hourmant M, Rougier JP, Hirn M, Dantal J, Baatard R, Cantarovich D, Jacques Y, Soulillou JP. Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation. 1991;52:291–296. [PubMed]
43. Stoppa AM, Maraninchi D, Blaise D, Viens P, Hirn M, Olive D, Reiffers J, Milpied N, Gaspard MH, Mawas C. Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III–IV acute graft-versus-host disease. Transpl Int. 1991;4:3–7. [PubMed]
44. Cantor JM, Ginsberg MH, Rose DM. Integrin-associated proteins as potential therapeutic targets. Immunol Rev. 2008;223:236–251. [PubMed]
45. Springer T, Galfre G, Secher DS, Milstein C. Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol. 1979;9:301–306. [PubMed]
46. Plow EF, Zhang L. A MAC-1 attack: integrin functions directly challenged in knockout mice. J Clin Invest. 1997;99:1145–1146. [PMC free article] [PubMed]
47. McFarland HI, Nahill SR, Maciaszek JW, Welsh RM. CD11b (Mac-1): a marker for CD8+ cytotoxic T cell activation and memory in virus infection. J Immunol. 1992;149:1326–1333. [PubMed]
48. Springer TA, Thompson WS, Miller LJ, Schmalstieg FC, Anderson DC. Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis. J Exp Med. 1984;160:1901–1918. [PMC free article] [PubMed]
49. Miller LJ, Bainton DF, Borregaard N, Springer TA. Stimulated mobilization of monocyte Mac-1 and p150,95 adhesion proteins from an intracellular vesicular compartment to the cell surface. J Clin Invest. 1987;80:535–544. [PMC free article] [PubMed]
50. Todd RF, 3rd, Arnaout MA, Rosin RE, Crowley CA, Peters WA, Babior BM. Subcellular localization of the large subunit of Mo1 (Mo1 alpha; formerly gp 110), a surface glycoprotein associated with neutrophil adhesion. J Clin Invest. 1984;74:1280–1290. [PMC free article] [PubMed]
51. Vedder NB, Harlan JM. Increased surface expression of CD11b/CD18 (Mac-1) is not required for stimulated neutrophil adherence to cultured endothelium. J Clin Invest. 1988;81:676–682. [PMC free article] [PubMed]
52. Diamond MS, Springer TA. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol. 1993;120:545–556. [PMC free article] [PubMed]
53. Davey PC, Zuzel M, Kamiguti AS, Hunt JA, Aziz KA. Activation-dependent proteolytic degradation of polymorphonuclear CD11b. Br J Haematol. 2000;111:934–942. [PubMed]
54. Phillipson M, Heit B, Colarusso P, Liu L, Ballantyne CM, Kubes P. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J Exp Med. 2006;203:2569–2575. [PMC free article] [PubMed]
55. Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL, Springer TA. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol. 1993;120:1031–1043. [PMC free article] [PubMed]
56. Diamond MS, Staunton DE, de Fougerolles AR, Stacker SA, Garcia-Aguilar J, Hibbs ML, Springer TA. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18) J Cell Biol. 1990;111:3129–3139. [PMC free article] [PubMed]
57. Gahmberg CG. Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Curr Opin Cell Biol. 1997;9:643–650. [PubMed]
58. Altieri DC, Bader R, Mannucci PM, Edgington TS. Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol. 1988;107:1893–1900. [PMC free article] [PubMed]
59. Beller DI, Springer TA, Schreiber RD. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med. 1982;156:1000–1009. [PMC free article] [PubMed]
60. Ehlers MR. CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect. 2000;2:289–294. [PubMed]
61. Diamond MS, Staunton DE, Marlin SD, Springer TA. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell. 1991;65:961–971. [PubMed]
62. Lub M, van Kooyk Y, Figdor CG. Competition between lymphocyte function-associated antigen 1 (CD11a/CD18) and Mac-1 (CD11b/CD18) for binding to intercellular adhesion molecule-1 (CD54). J Leukoc Biol. 1996;59:648–655. [PubMed]
63. Ding ZM, Babensee JE, Simon SI, Lu H, Perrard JL, Bullard DC, Dai XY, Bromley SK, Dustin ML, Entman ML, Smith CW, Ballantyne CM. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol. 1999;163:5029–5038. [PubMed]
64. Yakubenko VP, Lishko VK, Lam SC, Ugarova TP. A molecular basis for integrin alphaMbeta 2 ligand binding promiscuity. J Biol Chem. 2002;277:48635–48642. [PubMed]
65. Zhang L, Plow EF. Amino acid sequences within the alpha subunit of integrin alpha M beta 2 (Mac-1) critical for specific recognition of C3bi. Biochemistry. 1999;38:8064–8071. [PubMed]
66. Weber KS, Klickstein LB, Weber C. Specific activation of leukocyte beta2 integrins lymphocyte function-associated antigen-1 and Mac-1 by chemokines mediated by distinct pathways via the alpha subunit cytoplasmic domains. Mol Biol Cell. 1999;10:861–873. [PMC free article] [PubMed]
67. Heit B, Colarusso P, Kubes P. Fundamentally different roles for LFA-1, Mac-1 and alpha4-integrin in neutrophil chemotaxis. J Cell Sci. 2005;118:5205–5220. [PubMed]
68. Fagerholm SC, Hilden TJ, Nurmi SM, Gahmberg CG. Specific integrin alpha and beta chain phosphorylations regulate LFA-1 activation through affinity-dependent and -independent mechanisms. J Cell Biol. 2005;171:705–715. [PMC free article] [PubMed]
69. Fagerholm SC, Varis M, Stefanidakis M, Hilden TJ, Gahmberg CG. alpha-Chain phosphorylation of the human leukocyte CD11b/CD18 (Mac-1) integrin is pivotal for integrin activation to bind ICAMs and leukocyte extravasation. Blood. 2006;108:3379–3386. [PubMed]
70. Muchowski PJ, Zhang L, Chang ER, Soule HR, Plow EF, Moyle M. Functional interaction between the integrin antagonist neutrophil inhibitory factor and the I domain of CD11b/CD18. J Biol Chem. 1994;269:26419–26423. [PubMed]
71. Jiang N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res. 1998;788:25–34. [PubMed]
72. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34:2543–2548. [PubMed]
73. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994;330:956–961. [PubMed]
74. Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003;108:1316–1323. [PubMed]
75. Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP, Ferguson JJ, 3rd, Willerson JT, Weisman HF, Topol EJ. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059–2065. [PubMed]
76. Inoue T, Sakai Y, Fujito T, Hoshi K, Hayashi T, Takayanagi K, Morooka S. Clinical significance of neutrophil adhesion molecules expression after coronary angioplasty on the development of restenosis. Thromb Haemost. 1998;79:54–58. [PubMed]
77. Pietersma A, Kofflard M, de Wit LE, Stijnen T, Koster JF, Serruys PW, Sluiter W. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91:1320–1325. [PubMed]
78. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol. 1996;28:345–353. [PubMed]
79. Schwarz M, Nordt T, Bode C, Peter K. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2) Thromb Res. 2002;107:121–128. [PubMed]
80. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A. 1998;95:10134–10139. [PubMed]
81. Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ. Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement. 1987;4:61–74. [PubMed]
82. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18) J Immunol. 1996;156:1235–1246. [PubMed]
83. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross GD. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol. 1999;162:2281–2290. [PubMed]
84. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, Ross GD. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 2003;63:9023–9031. [PubMed]
85. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18) J Immunol. 1999;163:3045–3052. [PubMed]
86. Diamond MS, Springer TA. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol. 1993;120:545–556. [PMC free article] [PubMed]
87. Eisenhardt SU, Schwarz M, Schallner N, Soosairajah J, Bassler N, Huang D, Bode C, Peter K. Generation of activation-specific human anti-alphaMbeta2 single-chain antibodies as potential diagnostic tools and therapeutic agents. Blood. 2007;109:3521–3528. [PubMed]
88. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest. 1994;94:1722–1728. [PMC free article] [PubMed]
89. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007;25:619–647. [PMC free article] [PubMed]
90. Puig-Kroger A, Sanz-Rodriguez F, Longo N, Sanchez-Mateos P, Botella L, Teixido J, Bernabeu C, Corbi AL. Maturation-dependent expression and function of the CD49d integrin on monocyte-derived human dendritic cells. J Immunol. 2000;165:4338–4345. [PubMed]
91. Rosen GD, Sanes JR, LaChance R, Cunningham JM, Roman J, Dean DC. Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis. Cell. 1992;69:1107–1119. [PubMed]
92. Nieto M, Gomez M, Sanchez-Mateos P, Fernandez E, Marazuela M, Sacedon R, Varas A, Gonzalez-Amaro R, Zapata AG, Toribio ML, Sanchez-Madrid F. Expression of functionally active alpha 4 beta 1 integrin by thymic epithelial cells. Clin Exp Immunol. 1996;106:170–178. [PubMed]
93. Prosper F, Stroncek D, McCarthy JB, Verfaillie CM. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of alpha4 beta1 integrin expression and function. J Clin Invest. 1998;101:2456–2467. [PMC free article] [PubMed]
94. Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by α4 integrins are essential in placental and cardiac development. Development. 1995;121:549–560. [PubMed]
95. Cunningham SA, Rodriguez JM, Arrate MP, Tran TM, Brock TA. JAM2 interacts with alpha4beta1. Facilitation by JAM3. J Biol Chem. 2002;277:27589–27592. [PubMed]
96. Ebnet K, Suzuki A, Ohno S, Vestweber D. Junctional adhesion molecules (JAMs): more molecules with dual functions? J Cell Sci. 2004;117:19–29. [PubMed]
97. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol. 1999;72:209–253. [PubMed]
98. Alon R, Kassner PD, Carr MW, Finger EB, Hemler ME, Springer TA. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol. 1995;128:1243–1253. [PMC free article] [PubMed]
99. Berlin C, Bargatze RF, von Andrian UH, Szabo MC, Hasslen SR, Nelson RD, Berg EL, Erlandsen SL, Butcher EC. α4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell. 1995;80:413–422. [PubMed]
100. Sims TN, Dustin ML. The immunological synapse: integrins take the stage. Immunol Rev. 2002;186:100–117. [PubMed]
101. Mittelbrunn M, Molina A, Escribese MM, Yanez-Mo M, Escudero E, Ursa A, Tejedor R, Mampaso F, Sanchez-Madrid F. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci U S A. 2004;101:11058–11063. [PubMed]
102. Reedquist KA, Ross E, Koop EA, Wolthuis RM, Zwartkruis FJ, van Kooyk Y, Salmon M, Buckley CD, Bos JL. The small GTPase, Rap1, mediates CD31-induced integrin adhesion. J Cell Biol. 2000;148:1151–1158. [PMC free article] [PubMed]
103. Bos JL, de Rooij J, Reedquist KA. Rap1 signalling: adhering to new models. Nat Rev Mol Cell Biol. 2001;2:369–377. [PubMed]
104. Goldfinger LE, Han J, Kiosses WB, Howe AK, Ginsberg MH. Spatial restriction of α4 integrin phosphorylation regulates lamellipodial stability and α4β1-dependent cell migration. J Cell Biol. 2003;162:731–741. [PMC free article] [PubMed]
105. Han J, Rose DM, Woodside DG, Goldfinger LE, Ginsberg MH. Integrin α4β1-dependent cell migration requires both phosphorylation and de-phosphorylation of the a4 cytoplasmic domain. J Biol Chem. 2003;278:34845–34853. [PubMed]
106. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature. 1992;356:63–66. [PubMed]
107. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24–32. [PubMed]
108. Laberge S, Rabb H, Issekutz TB, Martin JG. Role of VLA-4 and LFA-1 in allergen-induced airway hyperresponsiveness and lung inflammation in the rat. Am J Respir Crit Care Med. 1995;151:822–829. [PubMed]
109. Offner H, Subramanian S, Parker SM, Wang C, Afentoulis ME, Lewis A, Vandenbark AA, Hurn PD. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol. 2006;176:6523–6531. [PubMed]
110. Laffon A, Garcia-Vicuna R, Humbria A, Postigo AA, Corbi AL, de Landazuri MO, Sanchez-Madrid F. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J Clin Invest. 1991;88:546–552. [PMC free article] [PubMed]
111. Podolsky DK. Inflammatory bowel disease (1) N Engl J Med. 1991;325:928–937. [PubMed]
112. Jackson DY. α4 integrin antagonists. Curr Pharm Des. 2002;8:1229–1253. [PubMed]
113. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev. 2002;22:146–167. [PubMed]
114. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185–195. [PubMed]
115. Hemler ME, Elices MJ, Parker C, Takada Y. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol Rev. 1990;114:45–65. [PubMed]
116. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov. 2005;4:510–518. [PubMed]
117. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–374. [PubMed]
118. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–381. [PubMed]
119. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362–368. [PubMed]
120. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol. 2004;17:365–370. [PubMed]
121. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924–933. [PMC free article] [PubMed]
122. Kummer C, Ginsberg MH. New approaches to blockade of alpha4-integrins, proven therapeutic targets in chronic inflammation. Biochem Pharmacol. 2006;72:1460–1468. [PubMed]
123. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood. 1998;92:3240–3249. [PubMed]
124. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation. 2002;106:379–385. [PubMed]